Kiky Martha Ariesaka
Department of Parasitology, Faculty of Medicine, State University of Malang, Malang, Indonesia

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

In Silico Docking and ADME-Tox evaluation of annonacin : Addressing contradictions in antimalarial evidence against PfDHODH and PfLDH Anindya Zerlina Tsaqif; Khodijah Khodijah; Fahrizal Ryuzen Prayogi; Moh Mirza Nuryady; Kiky Martha Ariesaka
Sains Medika: Jurnal Kedokteran dan Kesehatan Vol. 16 No. 2 (2025): December 2025
Publisher : Faculty of Medicine, Universitas Islam Sultan Agung (UNISSULA), Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30659/sainsmed.v16i2.39412

Abstract

The rise of resistance to current antimalarial therapies highlights the urgent need for novel drug candidates.Annona muricata contains phenolic compounds, particularly annonaceous acetogenins, known for theirbioactive properties and cytotoxicity. This study investigates the binding affinity of Annonacin to themalaria target proteins PfDHODH and PfLDH and assesses its toxicity and pharmacokinetic propertiesusing in silico methods. Molecular docking was performed using Molegro Virtual Docker (MVD) version6.0 to explore Annonacin’s binding interactions with PfDHODH and PfLDH. Toxicity was evaluatedusing ProTox-II, focusing on cytotoxicity and LD50 values. Pharmacokinetic parameters, includinggastrointestinal absorption and compliance with Lipinski’s Rule of Five, were analysed using SwissADME.Docking analyses indicated stable complexes of Annonacin with both PfDHODH and PfLDH, suggestingstrong inhibitory potential. Toxicity evaluation revealed significant cytotoxic effects, with an LD50 of400 mg/kg, placing Annonacin in Toxicity Class IV, indicating risk upon ingestion. Pharmacokineticassessments identified challenges, including low gastrointestinal absorption and a violation of Lipinski’srule due to Annonacin’s high molecular weight. Annonacin demonstrates notable antimalarial potential;however, its development is limited by safety issues and pharmacokinetic constraints. Optimisation effortsare essential to enhance efficacy and safety, laying the groundwork for future research and development.